Sanofi US (FKA Sanofi-Aventis)
Registered Principal Details
Business Or Interest:
Pharmaceutical Manufacturing
Lobbying Interests:
All matters affecting the pharmaceuticals and health care industries.
CEO Name:
Jez Moulding
Senior Director
Pharmaceutical Manufacturing
Lobbying Interests:
All matters affecting the pharmaceuticals and health care industries.
CEO Name:
Jez Moulding
Senior Director
Contact
DH
Debbie Hayes
55 Corporate Drive, Mail Stop 5A-500A P.O. Box 5925
Bridgewater, NJ 08807
(501) 868-3380
debbie.hayes@sanofi.com
http://www.sanofi.us
55 Corporate Drive, Mail Stop 5A-500A P.O. Box 5925
Bridgewater, NJ 08807
(501) 868-3380
debbie.hayes@sanofi.com
http://www.sanofi.us
Authorized Lobbyists
| Lobbyist Name | Exclusive Duties | Authorized On | Withdrawn On |
|---|
Lobbying Interests
Legislative Bills/Resolutions
Assembly Bill 179
Relating to: access to investigational drugs, devices, and biological products and limitations on liability related to their use.
Bill Text and History
5/1/2015
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Relating to: access to investigational drugs, devices, and biological products and limitations on liability related to their use.
Bill Text and History
Other
Notification Date5/1/2015
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Assembly Bill 203
Relating to: supply and use of epinephrine auto-injectors by certain authorized entities. (FE)
Bill Text and History
5/8/2015
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Relating to: supply and use of epinephrine auto-injectors by certain authorized entities. (FE)
Bill Text and History
For
Notification Date5/8/2015
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Senate Bill 125
Relating to: access to investigational drugs, devices, and biological products and limitations on liability related to their use.
Bill Text and History
5/1/2015
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Relating to: access to investigational drugs, devices, and biological products and limitations on liability related to their use.
Bill Text and History
Other
Notification Date5/1/2015
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Senate Bill 138
Relating to: information to be provided by insurers about health care plans offered on the American health benefit exchange.
Bill Text and History
5/8/2015
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Relating to: information to be provided by insurers about health care plans offered on the American health benefit exchange.
Bill Text and History
For
Notification Date5/8/2015
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Senate Bill 139
Relating to: supply and use of epinephrine auto-injectors by certain authorized entities. (FE)
Bill Text and History
2015 Wisconsin Act 35
5/1/2015
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Comments
Support expanded access to life-saving epinephrine auto injectors
Relating to: supply and use of epinephrine auto-injectors by certain authorized entities. (FE)
Bill Text and History
2015 Wisconsin Act 35
For
Notification Date5/1/2015
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Comments
Support expanded access to life-saving epinephrine auto injectors
Senate Joint Resolution 21
Relating to: proclaiming November 2015 as diabetes awareness month.
Bill Text and History
4/8/2015
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Comments
Sanofi is a strong supporter of public policy that allows Wisconsin Citizens access to diabetes care and prevention.
http://www.sanofidiabetes.com
Relating to: proclaiming November 2015 as diabetes awareness month.
Bill Text and History
For
Notification Date4/8/2015
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Comments
Sanofi is a strong supporter of public policy that allows Wisconsin Citizens access to diabetes care and prevention.
http://www.sanofidiabetes.com
Budget Bill Subjects
Biennial budget bill treatment of matter relating to
Health Services: Medical Assistance - General
Health Services: Medical Assistance - General
Notification Date
4/8/2015
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
4/8/2015
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Topics Not Yet Assigned A Bill Or Rule Number
Sanofi is interested in expanded "Right to Try" legislation that expand patient's access to investigational medicines.
Development, drafting or introduction of a proposal relating to
Sanofi is interested in expanded "Right to Try" legislation that expand patient's access to investigational medicines.
Sanofi is interested in expanded "Right to Try" legislation that expand patient's access to investigational medicines.
Action Intended To Affect
Legislative matter
Notification Date
4/8/2015
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Legislative matter
Notification Date
4/8/2015
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Development, drafting or introduction of a proposal relating to
Sanofi is interested in modifications to Chapter 450, the Pharmacy Practice Act.
Sanofi is interested in modifications to Chapter 450, the Pharmacy Practice Act.
Action Intended To Affect
Both Legislative matter and rule
Notification Date
4/8/2015
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Both Legislative matter and rule
Notification Date
4/8/2015
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Sanofi is intersted in matters that expand patient access to Medicaid and public assistance programs.
Development, drafting or introduction of a proposal relating to
Sanofi is intersted in matters that expand patient access to Medicaid and public assistance programs.
Sanofi is intersted in matters that expand patient access to Medicaid and public assistance programs.
Action Intended To Affect
Both Legislative matter and rule
Notification Date
4/8/2015
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Both Legislative matter and rule
Notification Date
4/8/2015
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Sanofi is interested in matters that expand public access to epinephrine auto injectors for the treatment of anaphylaxis and severe asthmatic episodes.
Development, drafting or introduction of a proposal relating to
Sanofi is interested in matters that expand public access to epinephrine auto injectors for the treatment of anaphylaxis and severe asthmatic episodes.
Sanofi is interested in matters that expand public access to epinephrine auto injectors for the treatment of anaphylaxis and severe asthmatic episodes.
Action Intended To Affect
Legislative matter
Notification Date
4/8/2015
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Legislative matter
Notification Date
4/8/2015
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Sanofi is interested in policy that promotes transparency and patient literacy in insurance policy benefits language.
Development, drafting or introduction of a proposal relating to
Sanofi is interested in policy that promotes transparency and patient literacy in insurance policy benefits language.
Sanofi is interested in policy that promotes transparency and patient literacy in insurance policy benefits language.
Action Intended To Affect
Legislative matter
Notification Date
4/8/2015
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Legislative matter
Notification Date
4/8/2015
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Development, drafting or introduction of a proposal relating to
Items related to transparency in pharmacy benefit language
Items related to transparency in pharmacy benefit language
Action Intended To Affect
Both Legislative matter and rule
Notification Date
1/21/2015
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Both Legislative matter and rule
Notification Date
1/21/2015
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Total Lobbying Effort
| 2015 January - June |
2015 July - December |
2016 January - June |
2016 July - December |
Total | |
|---|---|---|---|---|---|
| Total Lobbying Expenditures | 2015 January - June $18,906.30 |
2015 July - December $17,179.32 |
2016 January - June $17,701.43 |
2016 July - December $0.00 |
Total $53,787.05 |
| Total Hours Communicating | 2015 January - June 40.00 |
2015 July - December 15.50 |
2016 January - June 23.00 |
2016 July - December 0.00 |
Total 78.50 |
| Total Hours Other | 2015 January - June 22.50 |
2015 July - December 8.50 |
2016 January - June 16.50 |
2016 July - December 0.00 |
Total 47.50 |
Percent Allocation of Lobbying Effort
Legislative Bills/Resolutions
Relating to: access to investigational drugs, devices, and biological products and limitations on liability related to their use.
| 2015 January - June |
2015 July - December |
2016 January - June |
2016 July - December |
Total |
|---|---|---|---|---|
| 2015 January - June 5% |
2015 July - December |
2016 January - June 5% |
2016 July - December |
Total 4% |
Relating to: proclaiming November 2015 as diabetes awareness month.
| 2015 January - June |
2015 July - December |
2016 January - June |
2016 July - December |
Total |
|---|---|---|---|---|
| 2015 January - June 10% |
2015 July - December 20% |
2016 January - June 15% |
2016 July - December |
Total 13% |
Relating to: supply and use of epinephrine auto-injectors by certain authorized entities. (FE)
| 2015 January - June |
2015 July - December |
2016 January - June |
2016 July - December |
Total |
|---|---|---|---|---|
| 2015 January - June 12% |
2015 July - December |
2016 January - June 10% |
2016 July - December |
Total 10% |
Relating to: supply and use of epinephrine auto-injectors by certain authorized entities. (FE)
| 2015 January - June |
2015 July - December |
2016 January - June |
2016 July - December |
Total |
|---|---|---|---|---|
| 2015 January - June 13% |
2015 July - December |
2016 January - June 10% |
2016 July - December |
Total 10% |
Relating to: information to be provided by insurers about health care plans offered on the American health benefit exchange.
| 2015 January - June |
2015 July - December |
2016 January - June |
2016 July - December |
Total |
|---|---|---|---|---|
| 2015 January - June 20% |
2015 July - December 20% |
2016 January - June 15% |
2016 July - December |
Total 19% |
Relating to: access to investigational drugs, devices, and biological products and limitations on liability related to their use.
| 2015 January - June |
2015 July - December |
2016 January - June |
2016 July - December |
Total |
|---|---|---|---|---|
| 2015 January - June |
2015 July - December |
2016 January - June 5% |
2016 July - December |
Total 2% |
Budget Bill Subjects
| 2015 January - June |
2015 July - December |
2016 January - June |
2016 July - December |
Total |
|---|---|---|---|---|
| 2015 January - June 10% |
2015 July - December |
2016 January - June 20% |
2016 July - December |
Total 11% |
Administrative Rulemaking Proceedings
No administrative rulemaking proceedings found.
Topics Not Yet Assigned A Bill Or Rule Number
| 2015 January - June |
2015 July - December |
2016 January - June |
2016 July - December |
Total |
|---|---|---|---|---|
| 2015 January - June 10% |
2015 July - December 10% |
2016 January - June |
2016 July - December |
Total 7% |
Sanofi is intersted in matters that expand patient access to Medicaid and public assistance programs.
| 2015 January - June |
2015 July - December |
2016 January - June |
2016 July - December |
Total |
|---|---|---|---|---|
| 2015 January - June |
2015 July - December 10% |
2016 January - June |
2016 July - December |
Total 2% |
| 2015 January - June |
2015 July - December |
2016 January - June |
2016 July - December |
Total |
|---|---|---|---|---|
| 2015 January - June |
2015 July - December 10% |
2016 January - June |
2016 July - December |
Total 2% |
Minor Efforts
(Time spent on matters each of which accounted for less than 10% of the organization's lobbying.)
Other Matters
Includes time spent on:
- Gubernatorial nominations
- Matters on which the organization made no lobbying communication